Patients give telehealth rave reviews: We look at new data from JD Power and unpack what’s driving consumer use and satisfaction
Digital health startups to watch: We spotlight funding rounds from senior-focused mental health company Rippl and online vision care benefits platform XP Health, and detail why they’re worth watching.
At the end of the day, we think the value of Hims & Hers’ new sex report lies more in the titillating topic than the novelty of its findings.
The online grocery giant is eyeing “Food as Medicine” for future growth. We detail how it could support insurers’ social determinants of health programs.
Primary care disruptors could reel in patients with $0 telehealth: We unpack Blue Cross MA’s new tie-up with Carbon and Health and Firefly Health and explain why consumers will ultimately benefit.
VR tech enters the Brain Computing space: VR headsets can now read facial muscles and eye movements to interact with PCs or communicate—advancements that could make the tech less invasive than neural implants.
Zooming in on young Hispanics and healthcare: We look at the US Hispanic population’s attitudes toward healthcare and what providers and marketers need to do to get the younger generation engaged.
Google makes Fitbit data easier for doctors to parse with Cloud integration: But that may not be enough of a lure to help it make up ground in the healthcare cloud market.
Humana, CVS battle for Cano Health: We unpack why the two companies are going after primary care disruptor Cano, and posit which player might have the upper hand.
Smartwatches and fitness trackers face slump: Rising inflation, economic uncertainty, and slowing innovation are ending pandemic-era hyper-growth as the segment matures.
Meta tries to skirt around ATT: A lawsuit alleges that the social media giant injected tracking code into its in-app browsers, breaking privacy rules.
Nvidia’s new edge AI computing platform highlights the need to protect surgical robots and medical devices from hacking.
Pfizer expands its agreement with CytoReason by five years to boost AI’s role in drug development. We spotlight the trend in the pharma world.